[Treatment of chronic heart failure with positive inotropic agents].
Prognosis of heart failure patients remains poor and stimulates research of new active drugs and therapeutic improvements. Besides diuretic and vasodilating agents, the place of positive inotropic drugs remains to be defined. Long term benefit remains to be demonstrated for Milrinone, Enoximone and Digitalis. However, absence of benefit has been established with Amrinone and beta adrenoceptor agonists. Too many uncontrolled studies have complicated the accurate evaluation of efficacy of these positive inotropic drugs. Purpose of heart failure treatment remains to improve functional status without deterioration of myocardial fibers contractility. The respective roles of cAMP, gAMP and intracellular calcium concerning myocardial fiber longevity remains to be clarified.
Lechat
P
P
D000318:Adrenergic beta-Agonists / Q000494:pharmacology / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D004071:Digitalis Glycosides / Q000627:therapeutic use; D004361:Drug Tolerance; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality; D006801:Humans; D010101:Oxygen Consumption / Q000187:drug effects; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use
D000318:Adrenergic beta-Agonists; D000889:Anti-Arrhythmia Agents; D002316:Cardiotonic Agents; D004071:Digitalis Glycosides; D010726:Phosphodiesterase Inhibitors
Traitement de l'insuffisance cardiaque chronique par les inotropes positifs.